RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
Italian pharma major Recordati has entered into a collaboration and license agreement with US mRNA specialist Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for ...
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, ...
Investing.com -- Italian pharmaceutical company Recordati has formed a strategic collaboration with Moderna to develop and ...
CAMBRIDGE, MA / ACCESSWIRE / May 19, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window One of the ...
- Initial data readout for patients with PA and MMA expected in the first half of 2023 - Interim data from healthy individuals, reported earlier this year, showed that BBP-671 was detected in plasma ...
Background Both host and microbe metabolism of tryptophan (Trp) is altered in diabetes; however, the molecular mechanisms are ...
Metabolic disorders and organic acidemias comprise a diverse group of inherited conditions in which enzymatic deficiencies disrupt normal metabolic pathways. Such deficiencies lead to the accumulation ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results